Advanced small cell lung cancer (SCLC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Advanced Small Cell Lung Cancer (SCLC) is a rare, quickly progressing form of lung cancer. It disseminates much more quickly than non-small cell lung cancer. Anyone can be impacted, but long-term smokers are typically impacted. Lung cancer is the fifth most common cancer in women and the most common cancer in men worldwide. While lung cancer rates are on the decline in the United States, rising tobacco use in developing nations is contributing to an alarming rise in lung cancer rates there. Rapid growth and early spread are features of small cell lung cancer (SCLC). It's crucial to get treatment going right away. Clinical stage Ia (T1N0) patients may be considered for standard staging with surgical resection following treatment, but combined chemotherapy and radiation therapy is the recommended course of action. To the second cycle of chemotherapy, radiation therapy is typically added.

Description

Advanced Small Cell Lung Cancer (SCLC) is a rare, quickly progressing form of lung cancer. Compared to non-small cell lung cancer, it spreads much more quickly. Although it can affect anyone, it typically affects long-term smokers. Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are the two main subtypes of lung cancer. A little over 13% of lung cancer cases are SCLC. It is less frequent than NSCLC, claims the American Cancer Society (ACS). Cancer cells have a propensity to multiply quickly and spread more readily to other body parts in SCLC. As a result, the likelihood of a cure is decreased because the condition is frequently not discovered until the cancer has spread throughout the body. The cancer can, however, be effectively treated if SCLC is found early enough to be identified.

Advanced small cell lung cancer (SCLC) (Epidemiology)

Lung cancer is the most prevalent cancer in men and the fifth most prevalent cancer in women worldwide. While lung cancer rates are on the decline in the United States, rising tobacco use in developing nations is contributing to an alarming rise in lung cancer rates there. Around 2.09 million new cases of lung cancer and 1.76 million lung cancer deaths occur each year worldwide, according to the World Health Organization. According to relative levels of tobacco use, lung cancer, including all histologic subtypes, was more prevalent in high-income countries. The gender ratio has increased globally over the past 50 years, which in turn reflects trends in tobacco use. SCLC is more common in men than it is in women, just like lung cancer in general. Over the past 30 years, there has been a decrease in the incidence of SCLC in the United States, which is consistent with a reduction in smoking rates. From 23% in 1975 to 44% in 2010, the% of elderly patients with CME (andgt;70 years) increased in the US. SCLC is less common among African Americans than it is among white Americans, despite the fact that African American men and women smoke more than white Americans do.

Advanced small cell lung cancer (SCLC) -Current Market Size & Forecast Trends

The global SCLC market was valued at $4.75 billion in 2023. The use of immunotherapies and novel agents is projected to drive a CAGR of ~12% by 2035.

Small cell lung cancer (SCLC) is distinguished by quick development and early dissemination. Clinical stage Ia (T1N0) patients may be considered for standard staging with surgical resection after treatment, but combined chemotherapy and radiation therapy is the recommended course of action. The second cycle of chemotherapy is typically supplemented with radiation therapy. Approx. Treatment typically consists of a combination of platinum and thoracic radiation based on chemotherapy for the 30% of SCLC patients who have limited-stage disease at diagnosis (e.g., tumors contained to the hemispheric, mediastinal, or supraclavicular lymph nodes). given to bring about healing. Patients with complete or partial remissions of their disease should be offered prophylactic cranial irradiation (PCI). Patients receive combination chemotherapy for extensive SCLC, which is still incurable with current treatment plans (e.g., SCLC spread to the supraclavicular region or with distant metastases). In SCLC, a variety of chemotherapy combinations are effective, but platinum-based regimens are typically preferred. Immune checkpoint inhibitor (ICI) therapy has recently emerged, breaking the deadlock in the treatment of small cell lung cancer. Combination techniques are being studied, such as adding ICI to chemotherapy and radiotherapy. Despite the fact that some of these tactics had appreciable survival benefits and manageable side effects, many of them fell short and did not significantly improve. Furthermore, a new classification of SCLC based on genetic analysis has expanded knowledge of the disease and suggested potential new therapeutic avenues. Additionally, the identification of a few new therapeutic targets, including DDL3, CDK7, and PARP, has raised hopes for a better prognosis for patients with small cell lung cancer.

Report Highlights

Advanced small cell lung cancer (SCLC) - Current Market Trends

Advanced small cell lung cancer (SCLC) - Current & Forecasted Cases across the G8 Countries

Advanced small cell lung cancer (SCLC) - Market Opportunities and Sales Potential for Agents

Advanced small cell lung cancer (SCLC) - Patient-based Market Forecast to 2035

Advanced small cell lung cancer (SCLC) - Untapped Business Opportunities

Advanced small cell lung cancer (SCLC) - Product Positioning Vis-a-vis Competitors' Products

Advanced small cell lung cancer (SCLC) - KOLs Insight